Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
COCP Cocrystal Pharma Inc
- Stocks
- Healthcare
- NASDAQ: COCP
Price (delayed)
$1.49
Market cap
$15.16M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.57
Enterprise value
$9.81M
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses.
Highlights
Cocrystal Pharma's EPS has increased by 9% from the previous quarter and by 4.8% YoY
Cocrystal Pharma's net income has increased by 9% from the previous quarter and by 5% YoY
The company's equity has shrunk by 68% YoY and by 23% QoQ
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ
Key stats
What are the main financial stats of COCP
Market
Valuations
Earnings
Shares outstanding
10.17M
Market cap
$15.16M
Enterprise value
$9.81M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.08
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$16.06M
Net income
-$15.85M
EBIT
-$16.18M
EBITDA
-$16.07M
Free cash flow
-$14.92M
Per share
Balance sheet
Liquidity
EPS
-$1.57
EPS diluted
-$1.57
Free cash flow per share
-$1.47
Book value per share
$0.72
Revenue per share
$0
TBVPS
$1.05
Total assets
$10.66M
Total liabilities
$3.36M
Debt
$1.73M
Equity
$7.3M
Working capital
$6.9M
Debt to equity
0.24
Current ratio
4.57
Quick ratio
3.67
Net debt/EBITDA
0.33
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-102.4%
Return on equity
-135.1%
Return on invested capital
-551.5%
Return on capital employed
-185.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
COCP stock price
How has the Cocrystal Pharma stock price performed over time
Intraday
0%
1 week
-3.87%
1 month
-12.87%
1 year
-37.92%
YTD
-26.24%
QTD
0%
Financial performance
How have Cocrystal Pharma's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.06M
Net income
-$15.85M
Gross margin
N/A
Net margin
N/A
The operating income has grown by 10% from the previous quarter and by 9% YoY
Cocrystal Pharma's net income has increased by 9% from the previous quarter and by 5% YoY
Price vs fundamentals
How does COCP's price correlate with its fundamentals
Growth
What is Cocrystal Pharma's growth rate over time
Valuation
What is Cocrystal Pharma stock price valuation
P/E
N/A
P/B
2.08
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Cocrystal Pharma's EPS has increased by 9% from the previous quarter and by 4.8% YoY
The stock's P/B is 89% above its 5-year quarterly average of 1.1 and 22% above its last 4 quarters average of 1.7
The company's equity has shrunk by 68% YoY and by 23% QoQ
Efficiency
How efficient is Cocrystal Pharma business performance
Cocrystal Pharma's ROE has plunged by 131% YoY and by 20% from the previous quarter
The ROA has plunged by 94% YoY and by 14% from the previous quarter
COCP's return on invested capital is up by 12% year-on-year and by 2.5% since the previous quarter
Dividends
What is COCP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for COCP.
Financial health
How did Cocrystal Pharma financials performed over time
The total assets has plunged by 60% YoY and by 21% from the previous quarter
The company's quick ratio has shrunk by 60% YoY and by 10% QoQ
The debt is 76% less than the equity
COCP's debt to equity has soared by 200% YoY and by 26% QoQ
The company's equity has shrunk by 68% YoY and by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.